Bharat Immunologicals and Biologicals Corporation last traded at ₹9.04 (2026-10-13). Over the past month the stock moved -40.1%, three months the stock moved -47.9%, year the stock moved -58.8%. Its closing range over 52 weeks is ₹7.53 – ₹20.76, with the latest close 56.5% below the high.
Closing prices up to 2026-10-13.
Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.[1]
Business Overview:[1][2] BIBCL is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India, undertaking. It was established as a Public Sector Unit to achieve the production and supply of high-quality polio vaccine. The company had captured 60% of the total market share and was among the top 20 Biotech companies in Indiain India. Currently, it manufactures and produces a range of pharmaceutical products such as: a) Oral Polio Vaccines (OPV Vaccine) b) Diarrhea Management Kits c) BIB Sweet Tablets d) Hepatitis B vaccine e) Zinc Tablets, etc. In FY16, the company switched over to bOPV from tOPV. To add in product line, the company diversified into plasma-derived medicines and the Oral Cholera Vaccine.
In the latest quarter (Sep 2023), Bharat Immunologicals and Biologicals Corporation reported sales of ₹0.00 crore (-100.0%) and net profit of ₹-4.92 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Sep 2023 | 0.00 | -4.68 | – | -4.92 | -1.14 |
| Jun 2023 | 0.00 | -4.31 | – | -4.59 | -1.06 |
| Mar 2023 | 7.65 | -4.02 | -52.55 | -3.88 | -0.90 |
| Dec 2022 | 0.00 | -4.72 | – | -4.68 | -1.08 |
| Sep 2022 | 26.48 | -2.50 | -9.44 | -3.08 | -0.71 |
| Jun 2022 | 10.48 | -4.83 | -46.09 | -5.00 | -1.16 |
| Mar 2022 | 22.04 | -3.67 | -16.65 | -4.28 | -0.99 |
| Dec 2021 | 17.43 | 1.02 | 5.85 | -0.33 | -0.08 |
| Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -30.8% | +41.1% | -26.3% | +7.2% | -100.0% | -65.3% | -100.0% | -100.0% |
| Operating profit growth | – | – | -564.4% | – | -562.7% | – | – | – |
| Net profit growth | – | – | -359.1% | – | – | – | – | – |
| EPS growth | – | – | -357.8% | – | – | – | – | – |
| OPM % | 5.9% | -16.7% | -46.1% | -9.4% | – | -52.6% | – | – |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2023), Bharat Immunologicals and Biologicals Corporation reported sales of ₹45.00 crore (-42.3%) and net profit of ₹-17.00 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2023 | 45.00 | -18.00 | -41.00 | -17.00 | -3.95 |
| Mar 2022 | 78.00 | -5.00 | -6.00 | -9.00 | -2.03 |
| Mar 2021 | 85.00 | -21.00 | -24.00 | -18.00 | -4.19 |
| Mar 2020 | 67.00 | -10.00 | -16.00 | -10.00 | -2.36 |
| Mar 2019 | 84.00 | -9.00 | -11.00 | -6.00 | -1.34 |
| Mar 2018 | 35.00 | -8.00 | -23.00 | -4.00 | -0.99 |
| Mar 2017 | 124.00 | 13.00 | 10.00 | 7.00 | 1.51 |
| Mar 2016 | 128.00 | -4.00 | -3.00 | -6.00 | -1.44 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -12.3% | -3.1% | -71.8% | +140.0% | -20.2% | +26.9% | -8.2% | -42.3% |
| Operating profit growth | -233.3% | – | -161.5% | – | – | – | – | – |
| Net profit growth | -400.0% | – | -157.1% | – | – | – | – | – |
| EPS growth | -500.0% | – | -165.6% | – | – | – | – | – |
| OPM % | -3.0% | 10.0% | -23.0% | -11.0% | -16.0% | -24.0% | -6.0% | -41.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Bharat Immunologicals and Biologicals Corporation .
Get Free AI Stock Analysis FREE →No recent news available for Bharat Immunologicals and Biologicals Corporation .
Bharat Immunologicals and Biologicals Corporation shares were last quoted at ₹9.04 (+3.6% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Bharat Immunologicals and Biologicals Corporation has a price-to-earnings (P/E) ratio of -3.04 and a price-to-book (P/B) ratio of 0.64. The industry P/E is 53.33.
The 52-week high of Bharat Immunologicals and Biologicals Corporation is ₹22.61 and the 52-week low is ₹12.82.
The market capitalisation of Bharat Immunologicals and Biologicals Corporation is about ₹56.18 crore.
In the latest quarter (Sep 2023), Bharat Immunologicals and Biologicals Corporation reported sales of ₹0.00 crore (-100.0%) and net profit of ₹-4.92 crore, compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Bharat Immunologicals and Biologicals Corporation has a 3-year ROE of -23.00%, 3-year profit growth of -31.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 59.25% of Bharat Immunologicals and Biologicals Corporation .
Bharat Immunologicals and Biologicals Corporation belongs to the Pharmaceuticals & Drugs sector.